{"id":641021,"date":"2026-05-13T17:46:15","date_gmt":"2026-05-13T17:46:15","guid":{"rendered":"https:\/\/www.newsbeep.com\/us\/641021\/"},"modified":"2026-05-13T17:46:15","modified_gmt":"2026-05-13T17:46:15","slug":"creatv-bio-opens-clia-certified-laboratory-to-support-oncology-drug-development","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us\/641021\/","title":{"rendered":"Creatv Bio Opens CLIA-Certified Laboratory to Support Oncology Drug Development"},"content":{"rendered":"<p>MONMOUTH JUNCTION, N.J., May 13, 2026 \/PRNewswire\/ &#8212; Creatv Bio, a Division of Creatv MicroTech, Inc. (&#8220;Creatv&#8221;), a liquid biopsy-based cancer diagnostic testing company, recently opened its full service CLIA-certified laboratory in Monmouth Junction, NJ. This state-of-the-art facility expands the company&#8217;s capabilities to support Biopharma&#8217;s drug development and clinical trial testing.<\/p>\n<p>The new laboratory enables Creatv to offer its LifeTracDx\u00ae Blood Test, which measures Cancer Associated Macrophage-Like cells (CAMLs) and Circulating Tumor Cells (CTCs), to companies developing and conducting oncology drug trials. CAMLs have been shown to be detectable in the blood of most cancer patients in all subtypes of malignancies as well as predict treatment response to most therapies within 30-45 days following drug administration.<\/p>\n<p>The LifeTracDx\u00ae Test offers several key advantages to support Cancer Drug Development:<\/p>\n<p> Monitors Early Treatment Response \u2013 Enables assessment of drug efficacy well before traditional endpoints.<br \/>\n Improves Patient Selection \u2013 Sponsors can identify and exclude patients from trials not likely to respond to therapeutic intervention.<br \/>\n Companion \/ Complementary Diagnostics \u2013 Allows co-development of\u00a0drugs that target changes of specific tumor markers by monitoring blood, rather than tissue.<br \/>\n Monitors Biomarker Expression of Tumor Cells\u2013 Monitors drug target expression in real time from patients to determine downregulation and resistance to therapies.<br \/>\n Measures PD-L1 Expression for Immunotherapy \u00a0\u2013 Creatv offers the first blood test for detecting PD-L1 expression changes in patients and their subsequent response to PD-L1\/PD-1 checkpoint inhibitors.<\/p>\n<p>&#8220;The opening of our CLIA Laboratory now enables us to offer a fully equipped facility to deliver rapid, reliable\u00a0analyses to our pharmaceutical partners,&#8221; said Dr. Cha-Mei Tang, President and CEO of Creatv Bio. &#8221; This is a major step forward in accelerating cancer drug development.&#8221;<\/p>\n<p>About Creatv Bio<\/p>\n<p>Creatv Bio is a CLIA-certified cancer diagnostics company providing laboratory testing services to pharmaceutical companies for research and investigational purposes.<\/p>\n<p>The LifeTracDx\u00ae blood test is an analytically validated assay under research and development. Current research applications include evaluation of circulating biomarkers to support translational and exploratory studies.<\/p>\n<p>The assay is intended for research and investigational use only and is not for use in clinical diagnosis, prognosis, treatment selection, or disease monitoring.<\/p>\n<p>For a complete listing of our peer-reviewed publications and scientific posters, please visit our website at creatvbio.com.<\/p>\n<p>Creatv contacts:<\/p>\n<p>SOURCE Creatv MicroTech, Inc.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=PH58130&amp;Transmission_Id=202605131005PR_NEWS_USPR_____PH58130&amp;DateId=20260513\" style=\"border:0px; width:1px; height:1px;\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"MONMOUTH JUNCTION, N.J., May 13, 2026 \/PRNewswire\/ &#8212; Creatv Bio, a Division of Creatv MicroTech, Inc. (&#8220;Creatv&#8221;), a&hellip;\n","protected":false},"author":2,"featured_media":641022,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[59],"tags":[244,64020,276792,97,252,9968,253,851,71561,9969,247],"class_list":["post-641021","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health-care","tag-biotechnology","tag-clinical-trials-medical-discoveries","tag-creatv-microtech","tag-health","tag-health-care","tag-health-care-hospitals","tag-healthcare","tag-inc","tag-medical-equipment","tag-medical-pharmaceuticals","tag-pharmaceuticals"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/641021","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=641021"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/641021\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/641022"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=641021"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=641021"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=641021"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}